The FDA has sunk Travere Therapeutics’ hopes of winning approval for its kidney disease candidate this year by requesting changes to the proposed risk evaluation mitigation strategy (REMS) that are expected to delay the decision date by three months.

Matchpoint Therapeutics has been served $70 million in series A funds to fund its covalent molecule ambitions, prioritizing platform development and early discovery work.

In a development that sounds fit for a horror film, scientists at Stanford University have transplanted human brain cells into rats. These human-rat brain hybrids could be used to study conditions like autism and schizophrenia, potentially marking a major turning point in scientists’ ability to develop effective treatments.

Rates of septic shock, a serious complication of sepsis, are on the rise. With only antibiotics and symptomatic treatment available, biotech Inotrem hopes its investigational asset could be the first mechanism-based treatment for the life-threatening condition.

More than two months ago, Otonomy shifted focus to its phase 2 hearing loss med, hoping that an upcoming readout would be music to the ears of the company’s top brass.

Most neurostimulation devices can be manually adjusted by users and their caregivers to customize treatments for chronic pain, epilepsy, stroke recovery and more, but an implant newly approved by the FDA outsources some of those tweaks to artificial intelligence.

VigiLanz, which specializes in clinical software surveillance, debuted its latest tool to identify a greater number of eligible candidates for clinical trial enrollment.

The world of antiviral drug development largely operates under a simple paradigm: one bug, one drug. That is, most therapies are designed to target proteins that are unique to specific viruses, such as the COVID-19 vaccine or telaprevir for hepatitis C.

It’s highly unlikely that artificial intelligence will ever become intelligent enough to completely replace humans in the workplace—let alone overthrow the entire population in a sci-fi-style rebellion—but in the realm of healthcare, at least, the robots are making some progress.

Former Fierce 15 winner XACT Robotics collected its second FDA clearance of the year for its palm-sized interventional device.